The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir
Abstract
OBJECTIVE—To investigate the pharmacodynamic profile and duration of action for five subcutaneous doses of insulin detemir (0.1, 0.2, 0.4, 0.8, and 1.6 units/kg; 1 unit = 24 nmol) and one subcutaneous dose of NPH insulin (0.3 IU/kg; 1 IU = 6 nmol). RESEARCH DESIGN AND METHODS—This single-center, randomized, double-blind, six-period, crossover study was carried out as a 24-h isoglycemic clamp (7.2 mmol/l) in 12 type 1 diabetic patients. RESULTS—Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively. Interpolation of the dose-response relationships for AUCGIR (area under the glucose infusion rate curve) revealed that a detemir dose of 0.29 units/kg would provide the same effect as 0.3 IU/kg NPH but has a longer duration of action (16.9 vs. 12.7 h, respectively). Lower between-subject variability was observed for insulin detemir on duration of action (0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, P < 0.05) and GIRmax (maximal glucose infusion rate) (0.2 and 0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, both P < 0.05). Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOCEGP (area over the EGP curve) of 636 mg/kg (95% CI 279–879) vs. 584 (323–846) and an AUCPGU (area under the PGU curve) of 173 (47–316) vs. 328 (39–617) for 0.29 units/kg detemir vs. 0.3 IU/kg NPH, respectively. CONCLUSIONS—This study shows that insulin detemir provides a flat and protracted pharmacodynamic profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
INFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT*
Steele, R. (1959) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1959.tb44923.x · Cited by 1,670
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Self-citationFinegood, D. T., Bergman, R. N., & Vranic, M. (1987) · Diabetes · doi:10.2337/diab.36.8.914 · Cited by 546
The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036926.54824.37 · Cited by 429
Kurtzhals, P., Havelund, S., Jonassen, I., Kiehr, B., Larsen, U. D., Ribel, U., & Markussen, J. (1995) · Biochemical Journal · doi:10.1042/bj3120725 · Cited by 334
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294 · cited 1×
“The reduction of nocturnal hypoglycemic episodes found in the clinical studies could be clearly attributed to the reduced action peak observed with insulin detemir (20,21).”
BackgroundSelf-citationHome, P., Bartley, P., Russell-Jones, D., Hanaire-Broutin, H., Heeg, J.-E., Abrams, P., Landin-Olsson, M., Hylleberg, B., Lang, H., Draeger, E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1081 · Cited by 254
Self-citationOwens, D. R., Coates, P. A., Luzio, S. D., Tinbergen, J. P., & Kurzhals, R. (2000) · Diabetes Care · doi:10.2337/diacare.23.6.813 · Cited by 200
Comparison of the Soluble Basal Insulin Analog Insulin Detemir With NPH Insulin
Hermansen, K., Madsbad, S., Perrild, H., Kristensen, A., & Axelsen, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.296 · Cited by 174
Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304
Heinemann, L., Sinha, K., Weyer, C., Loftager, M., Hirschberger, S., & Heise, T. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00081.x · Cited by 158
Pieber, T. R., Draeger, E., Kristensen, A., & Grill, V. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01545.x · Cited by 122
Self-citationKurtzhals, P. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802746 · Cited by 118
Brunner, G. A., Sendlhofer, G., Wutte, A., Ellmerer, M., Søgaard, B., Siebenhofer, A., Hirschberger, S., Krejs, G. J., & Pieber, T. R. (2000) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2000-5887 · Cited by 110
Self-citationClinical Factors Influencing the Absorption of125I-NPH Insulin in Diabetic Patients
Kølendorf, K., Bojsen, J., & Deckert, T. (1983) · Hormone and Metabolic Research · doi:10.1055/s-2007-1018694 · Cited by 74
Clinical Pharmacology of Human Insulin
Heinemann, L., & Richter, B. (1993) · Diabetes Care · doi:10.2337/diacare.16.3.90 · Cited by 71
Radziuk, J., & Pye, S. (2002) · Diabetologia · doi:10.1007/s00125-002-0841-6 · Cited by 70
The Action Profiles of Human NPH Insulin Preparations
Starke, A. A. R., Heinemann, L., Hohmann, A., & Berger, M. (1989) · Diabetic Medicine · doi:10.1111/j.1464-5491.1989.tb01154.x · Cited by 69
Regittnig, W., Trajanoski, Z., Leis, H. J., Ellmerer, M., Wutte, A., Sendlhofer, G., Schaupp, L., Brunner, G. A., Wach, P., & Pieber, T. R. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1070 · Cited by 43
Self-citationHachey, D. L., Parsons, W. R., McKay, S. V., & Haymond, M. W. (1999) · Analytical Chemistry · doi:10.1021/ac990724x · Cited by 35
Powrie, J., Smith, G. D., Hennessy, T. R., Shojaee‐Moradie, F., Kelly, J., Sönksen, P. H., & JONES, R. H. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01458.x · Cited by 34
Wirkungsprofil von humanem Ultralente-Insulin im Vergleich mit humanem NPH-Insulin
Starke, A. A. R., Heinemann, L., Hohmann, A., & Berger, M. (2008) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2008-1066645 · Cited by 11
Cited by
Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell‐Jones, D., & Khan, R. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 557
Philis-Tsimikas, A., Charpentier, G., Clauson, P., Ravn, G. M., Roberts, V. L., & Thorsteinsson, B. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.020 · Cited by 278
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248
Klein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251
Self-citationInsulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Metadata
- Authors
- Plank, J., Bodenlenz, M., Sinner, F., Magnes, C., Görzer, E., Regittnig, W., Endahl, L. A., Draeger, E., Zdravkovic, M., & Pieber, T. R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2005-05-01
- Volume
- 28
- Issue
- 5
- Pages
- 1107-1112
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2130931445
- Cited by
- 271
- References
- 22
- FWCI
- 15.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.